Chemical Constituents and Pharmacological Properties of Capsule Gurmar - A New Anti-diabetic Formulation of Hamdard Laboratories (Waqf) Bangladesh
AbstractCapsule Gurmar is a new polyherbal Unani formulation developed by the R&D department of Hamdard Laboratories (Waqf) Bangladesh for management and treatment of diabetes. This study was aimed to investigate the chemical constituents and analgesic, antioxidant, neuropharmacological, cytotoxic, and hypoglycemic properties of the formulation using standard methods. Phytochemical tests on the hydromethanolic extract of the contents of the capsules showed the presence of carbohydrates, glycosides, saponins, steroids, flavonoids, alkaloids and tannins in the formulation. When tested by acetic acid-induced Writhing test, the extract at higher dose (400mg/kg) showed mild analgesic activity compared to standard drug Diclofenac-Na (10mg/kg). But, by Tail immersion method, the extract at the same dose showed moderate analgesic activity compared to the standard drug, Nalbuphine at 10mg/kg body weight. The Gurmar capsule extract exhibited high total antioxidant capacity (622.326 mg/g) and had high flavonoid (386.43 mg/g) and phenol (184.60 mg/g) contents. In the Hole cross and Open field tests, the extract displayed significant suppression of locomotor activity and exploratory behaviour of the mice. When subjected to Brine shrimp Lethality Bioassay, the extract was found to be significantly toxic to Brine shrimp nauplii (having L50 value of 3.16μg/ml). Glucose Tolerance Test (GTT) demonstrated quite strong hypoglycemic activity of the formulation, which significantly lowered the blood glucose level of the treated mice both at doses of 100 mg and 200mg/kg body weight. The hypoglycemic effect was comparable to that of the standard oral hypoglycemic drug, Metformin hydrochloride at the dose of 100mg/kg. These results indicate that Capsule Gurmar possesses mild analgesic, antioxidant, CNS depressant, cytotoxic, and hypoglycemic properties.
Key words: capsule Gurmar; chemical constituents; pharmacological properties; hypoglycemic effects.
S. J. Pharm. Sci. 3(1): 18-27
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.